扩张性心肌病的精密治疗:梦幻或范式转变?
Saad Javed1,2, Brian P Halliday1,2
1National Heart and Lung Institute, Imperial College London, UK.
Cambridge prisms. Precision medicine
|March 29, 2024
概括
精准医学提供个性化心肌病治疗,通过向治疗和减少干预来改善结果. 未来的研究将重点关注早期疾病预防机制,将护理从症状管理转向主动健康.
科学领域:
- 心脏病学 心脏病学
- 基因组学就是基因组学.
- 精准医学是一门精准的医学.
背景情况:
- 扩张性心肌病 (DCM) 是全球心力衰竭的主要原因,其特征是左心室扩张和功能障碍.
- 基因组医学的进步显著改善了对DCM遗传基础的理解.
- 罕见遗传变异的可变表达性受常见的遗传变异和环境因素的影响,使个性化治疗复杂化.
研究的目的:
- 探索精准医学在改善心肌病患者治疗结果方面的潜力.
- 通过先进的多组学和成像来研究DCM中的基因型特定疾病机制.
- 将重点转向早期疾病检测和预防心肌病的预防策略.
主要方法:
- 利用基因组医学的进步来理解DCM的遗传架构.
- 采用先进的心脏成像和多omics方法来阐明基因型特异性疾病机制.
- 研究常见的遗传变异和环境因素对疾病表现的影响.
主要成果:
- 精准医学有望通过量身定制治疗来改善患者的治疗结果并降低医疗保健成本.
- 了解遗传变异对于开发新型的,针对性治疗DCM至关重要.
- 识别早期疾病机制是实现心血管保健范式转变的关键.
结论:
- 在心肌病中,精准医学可以优化治疗效率,并最大限度地减少不必要的干预.
- 对早期疾病机制的进一步研究对于从疾病管理过渡到预防至关重要.
- 将基因组洞察与临床方法相结合,将推动心力衰竭预防和治疗的个性化策略.
更多相关视频
12:45Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing
Published on: December 11, 2017
10.5K
10:05Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine
Published on: July 7, 2016
8.3K
相关概念视频
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
162
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
162
Heart Failure Drugs: Inotropic Agents
578
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
578
